Oct. 4, 2019
James Jordan, President & CEO at Pittsburgh Life Sciences Greenhouse
James F. Jordan is President/CEO at Pittsburgh Life Sciences Greenhouse and a healthcare professor at Carnegie Mellon University. Mr. Jordan is an accomplished Fortune 20-level executive with strong experience in the industry, consulting, and academia and is a recognized expert in market development and guiding the successful formation of entrepreneurial start-up businesses in the life sciences and healthcare industries. Prior to joining the PLSG, Mr. Jordan served as Senior Vice President of a $3 billion division of McKesson Corporation and at Johnson & Johnson. He has leveraged this experience in several startup ventures and is active on several boards of directors. His experience also includes consulting engagements with numerous companies, including Medtronic, Frost & Sullivan, and Otsuka Pharmaceutical.
Most recently, Mr. Jordan published his second book, The Intellectual Property Pyramid Assessment: A Novel Method for Creating a Sustainable Competitive Advantage. This is a complement to his first book, Innovation, Commercialization, and Start-Ups in Life Sciences, which provides expert guidance for start-up life sciences companies, from initiation to exit. His third book, to be published in 2019, is titled, Health Systems: an Overview. This book details the U.S. healthcare system, market, and business models.
WEBVTT
00:00:04.900 --> 00:00:07.839
Welcome to the Latin MedTech leaders podcast.
00:00:08.169 --> 00:00:13.210
This is a weekly conversation with med tech leaders who have succeeded in Latin America.
00:00:14.529 --> 00:00:28.089
Today our guest is James Jordan and with these interview with Jim we start a new topic in our podcast, the EU MDR and how it could potentially impact the medical device business in Latin America.
00:00:28.870 --> 00:00:37.570
James, his presidency, he all at Pittsburgh, life sciences greenhouse and a healthcare professor or Carnegie Mellon university.
00:00:38.560 --> 00:00:44.590
GM is an accomplished fortune 20 level executive with external experience in the industry, consulting and academia.
00:00:45.520 --> 00:00:55.030
He's a recognized expert in market development and guiding the successful formation of intrepreneurial startup businesses in the life sciences and healthcare industries.
00:00:55.539 --> 00:01:05.769
Prior to joining the P L S G Jim served as senior vice president of a 3 billion division of my case and corporation and at Johnson and Johnson.
00:01:06.730 --> 00:01:12.549
Jim has leveraged these experience insurers that are ventures and he's active on Xero board of directors.
00:01:13.239 --> 00:01:20.829
He's experienced also includes consulting engagements with numerous companies including Metronic for us and Sullivan and or Tuka pharmaceutical.
00:01:21.640 --> 00:01:24.549
We're continually show, Jim, are you doing today?
00:01:25.000 --> 00:01:25.959
I am doing great.
00:01:26.019 --> 00:01:42.280
Actually our conversation has the advantage of this morning I had an executive in residence discussion, which is normally part of our weekly fun discussion and so we actually brought up some of these questions that you're answering me and so you've benefited from having more than one opinion.
00:01:42.810 --> 00:01:44.409
That'd be a fun conversation then.
00:01:46.450 --> 00:01:52.900
So first of all, Jim, I am very privileged I think to be in contact with you now.
00:01:53.260 --> 00:01:58.810
I went through your book and let me tell you, I mean some of the mentor works is magisterial is as fascinating.
00:01:58.840 --> 00:02:03.530
I didn't have much chance to go deeper into it, but I went through the first pages in that.
00:02:03.599 --> 00:02:10.750
It's really fascinating and the work that you guys are doing at uh, PL SGS, yes, Antarctic.
00:02:10.810 --> 00:02:21.870
So I'm very, very impressed with what you guys are doing and certainly a pleasure to be in contact and thank you for connect on the phone and to speak about these.
00:02:22.490 --> 00:02:25.650
EU NBR topic is topic hasn't been researched enough.
00:02:26.129 --> 00:02:37.319
And companies in the us and Europe have trouble understanding that the American region, even though it is very close to the U S I am really, really looking forward to hearing your thoughts on, on the topic.
00:02:37.479 --> 00:02:46.629
So the first question is, you know, shell medical technology companies still consider Europe as their first commercial market before they seek FDA approval.
00:02:46.900 --> 00:02:58.689
And so the general conversation that we had here today on that topic was the mentally separating out clinical trials from regulatory commercial approval.
00:02:59.270 --> 00:03:14.930
So the FDA has recognized certain countries that they will accept data for first in man and some of those things as data elements that they can file to the FDA, but that you have to have more than just those countries.
00:03:15.020 --> 00:03:26.000
So both Europe and Latin America are great places to gather early first in man data in places that might be, um, more friendly to work with.
00:03:26.001 --> 00:03:39.650
So from a regulatory perspective, the answer is yes, but from a commercialization perspective, I think the world has historically looked at Europe specifically as one sort of regulatory body.
00:03:40.340 --> 00:03:44.719
And on some aspects that's true, but for the most part it is not true.
00:03:45.199 --> 00:03:53.389
So you have to go country by country to clear a reimbursement to clear other hurdles besides the EU hurdles.
00:03:53.390 --> 00:04:06.770
So you know, we have found that if you think of the what I would call more of the chairman, Netherland Belgium countries, they're easier to commercialize in and say France, UK or Italy, they're much slower process.
00:04:06.800 --> 00:04:11.449
But in general your strategy has two aspects of it to consider.
00:04:11.569 --> 00:04:15.620
The first is I'm in money from an execution perspective.
00:04:15.919 --> 00:04:19.129
And the second consideration is funders.
00:04:19.130 --> 00:04:23.810
So one of the things you'll read in my startup book is you have three constituencies in a startup.
00:04:24.259 --> 00:04:27.529
You have the customer themselves who you eventually sell to.
00:04:28.009 --> 00:04:31.670
You have the investors and you have the acquirers.
00:04:32.569 --> 00:04:52.370
And so when you're considering, um, people that are going to invest in you, I think a lot of venture capitalists are hard pressed to find a company is an example where going to Europe for us, for commercialization ended up in any material revenue.
00:04:52.970 --> 00:05:02.540
And so although it ends up in getting first and man validation quicker in terms of scaling revenue, it has not.
00:05:02.839 --> 00:05:15.110
And so whether we're moving from the current state to more of a synergized EU that is more aligned with FDA, which is a different maybe heightened regulatory pathway.
00:05:15.139 --> 00:05:27.199
The question for VC would be if I have to put resources on the ground and have risk Europe other than getting me really clinical data is limited value, limited value.
00:05:27.560 --> 00:05:29.720
And so the same thing goes to the second question.
00:05:29.721 --> 00:05:34.279
Is Latin America a place where you know you would consider entering for us?
00:05:34.281 --> 00:05:44.120
So years ago Brazil and Argentina were great places to go to because of the quality of the physicians and the lower regulatory barriers.
00:05:44.120 --> 00:05:56.180
Today they are more like the U S and so again, the answer to that question would be the same as Europe in the sense that you would get your early clinical data there and you would be very pleased with that.
00:05:56.269 --> 00:06:01.399
Whether you would have a full commercial strategy, there is maybe not your primary action.
00:06:01.699 --> 00:06:05.629
So that goes to the, what's been your experience with EU in general?
00:06:05.630 --> 00:06:23.990
Which is also the same common of flattened America is very few investors have found that they have either materially reduced their time to market or materially increased post-approval revenue by having a European or a Latin America only strategy.
00:06:24.139 --> 00:06:30.410
However, I said the book is about commercialization, it's about the investors, and then it's about acquirers.
00:06:30.740 --> 00:06:52.939
So as companies get a little more mature and they're looking at increasing their exit value, having regulatory approvals across the globe is actually very attractive because Latin America and EU were both very, very large markets, particularly, you know, Argentina and Brazil historically has been where the U S has focused on, particularly for med tech.
00:06:53.420 --> 00:07:04.370
So it might not be my first strategy, but after I started commercializing in the U S anyone, how long I think I need to keep my company going before I sell it.
00:07:04.620 --> 00:07:06.889
Yeah, it's a matter of adding value, right?
00:07:07.370 --> 00:07:13.100
So if I can expand my market places and get approval, then that would be a good thing.
00:07:13.730 --> 00:07:20.480
So a lot of times what happens is when a company buys you, sometimes their hurdles go up.
00:07:20.509 --> 00:07:31.339
And so for example, I might be in Argentina where I'm working with a famous physician, I think in the old days of when I was at Boston scientific, working with Juan Perotti, right?
00:07:31.939 --> 00:07:36.500
And that company was me docs before it got bought by Boston scientific.
00:07:36.980 --> 00:07:37.759
It was a startup.
00:07:37.761 --> 00:07:47.509
They worked with the famous physician, you know, there was good synergy, there was good teamwork, and the government recognized the cash constraints of a startup company.
00:07:47.511 --> 00:07:59.509
And so they had certainly requirements of safety and efficacy, but then they maybe didn't talk about economic studies or other things that they might expect out of a Boston scientific or Jane J.
00:07:59.810 --> 00:08:11.589
So in that case, if I can get a regulatory approval in Argentina or Latin America or anywhere in Europe, and then I'm balling, that's by a company that regulatory approval goes with me.
00:08:11.589 --> 00:08:16.480
And for the acquirer, they may get into that country in a less costly way.
00:08:16.839 --> 00:08:17.620
We're an acquisition.
00:08:18.069 --> 00:08:20.709
And so that sort of answers the next question.
00:08:21.459 --> 00:08:25.810
The other question is, you know, what has been our company's experiences here?
00:08:26.230 --> 00:08:41.919
We've had three or four companies in our portfolio that went to Europe first they commercialized and they believed that they would be able to not have the same barriers in the U S and the fact of the matter is they did and they stumbled.
00:08:42.129 --> 00:08:44.950
They had a down round and it costs them more money.
00:08:45.190 --> 00:08:48.279
And I would say that the same experience in Latin America.
00:08:48.460 --> 00:09:07.080
So again, if Latin America is looking for cutting edge technologies to come to their individual countries ahead of time, certainly by participating and getting clinical data, they built global relationships and those global relationships are eventually going to pay dividends.
00:09:07.350 --> 00:09:13.049
They may not pay those dividends during the startup phase, they may pay them later on in the commercialization phase.
00:09:13.429 --> 00:09:14.389
Very well said.
00:09:14.419 --> 00:09:14.779
Yeah.
00:09:14.960 --> 00:09:27.740
Now if you think of that, that might not be such a terrible thing because when you're in the clinical trial, just getting data phase, usually companies in their investors have very specific money to give to do that.
00:09:27.740 --> 00:09:34.490
So you deliver the work, you get the money in the more longer relationship phase, you need a company to have a little bit more money.
00:09:34.879 --> 00:09:42.740
And if their post commercialized in the U S they actually have more cash and so maybe they can have a more broader relationship in the long run.
00:09:43.370 --> 00:09:45.799
So companies will never forget the people that did their clinical.
00:09:46.009 --> 00:09:46.490
Yeah.
00:09:46.549 --> 00:09:48.950
That's how I got started with first thing human trials.
00:09:48.951 --> 00:09:50.419
And that's what we continue to do it.
00:09:50.629 --> 00:09:55.700
And I'm actively lobbying the Colombian government to understand exactly what you're saying.
00:09:55.701 --> 00:09:58.259
And I'm actually trying to pass a new law in Columbia.
00:09:58.820 --> 00:10:02.809
I've met with the leadership at the Colombian Congress and everything about this.
00:10:02.811 --> 00:10:10.039
And it is a key opportunity for a country like Columbia to position itself as one of the top destinations in the world.
00:10:10.370 --> 00:10:21.590
Especially now that the country is looking to diversify its economy, uh, not to depend so much on oil and gas and murals, but uh, Chinese technology and innovation.
00:10:21.591 --> 00:10:36.919
I actually just last week there was a new ministry or secretary is, we called them in the U S the ministry of science, technology and innovation is a historical time for Columbia that regard because they finally understood that they have to take these investing times and value new patients as seriously.
00:10:37.070 --> 00:10:40.159
So, um, yeah, I agree with your statement.
00:10:40.440 --> 00:10:54.210
And I think that, you know, when you think about economic development for a nation, when those physicians are part of a landmark clinical trial, they end up being at all the top trade shows as being the person out there speaking about it.
00:10:54.389 --> 00:11:00.720
Whereas the U S physicians who may even have better brands and not get up and speak.
00:11:01.289 --> 00:11:21.629
And so what happens is, so if you just look at the time to what I would call relevance for a brand, so you're trying to make Columbia brand the time that those, you know, physicians can start participating and the time that they become attached to global companies because the global companies recognized them as the handful of people they want to do business with.
00:11:21.960 --> 00:11:28.679
And then other doctors and other institutions in the U S start inviting them to be visiting people.
00:11:29.129 --> 00:11:31.080
There's a company that I'm involved in.
00:11:31.470 --> 00:11:44.399
We started out with the training programs in Europe and when you're trying to train the U S physicians, you end up bringing over the Europeans to train the U S physicians, you know, same thing in Columbia, right?
00:11:44.399 --> 00:11:48.000
Or wherever you are in Latin America, you bring those physicians over to help train.
00:11:48.360 --> 00:12:07.129
Well, next thing you know, not only was that Colombian physician at this trade where you know they were in front of tens of thousands of people, but now the us top docs come in to be trained because you know the companies are naturally going to sell to the top people and your doctor's training those top people.
00:12:07.159 --> 00:12:10.759
Those are relationships that are forged for generation between the physicians.
00:12:11.929 --> 00:12:12.799
Well, that's my fault.
00:12:13.909 --> 00:12:22.549
Well, I appreciate finally getting to talk and thank you for being interested in my opinions and I thank you for buying my book and I hope you enjoy it.
00:12:22.580 --> 00:12:23.960
And you know, we do.
00:12:23.961 --> 00:12:25.009
Just for your own benefit.
00:12:25.039 --> 00:12:34.309
I have an academic website called healthcare data.center that has a lot of information on it about the health care system in the U S and my academic pursuit.
00:12:34.311 --> 00:12:43.250
So you should pick around there and maybe just some, I know if you look up the word valuations, there's some valuation standards up there that might be of interest to you.
00:12:43.789 --> 00:12:45.350
Health care data that's
00:12:45.429 --> 00:12:47.870
center instead of.com it's dot center.
00:12:48.159 --> 00:12:50.830
So maybe there's something that could value some of your constituents.
00:12:51.230 --> 00:12:51.590
Okay.
00:12:51.649 --> 00:12:52.269
Thank you again.
00:12:52.580 --> 00:12:53.179
I appreciate that.
00:12:53.409 --> 00:12:53.679
All right.
00:12:53.840 --> 00:12:59.240
If there's anything I can do to help anywhere, I mean, anytime you feel like doing anything about America, let me know.
00:12:59.240 --> 00:13:02.629
You already have my contact info and I look forward to keeping in touch.
00:13:03.049 --> 00:13:03.379
Perfect.
00:13:03.380 --> 00:13:04.250
Thank you so much.
00:13:04.639 --> 00:13:04.750
Thank you.
00:13:04.909 --> 00:13:05.179
Bye bye.
00:13:05.629 --> 00:13:06.200
All right, take care.
00:13:06.201 --> 00:13:06.440
Bye.
00:00:04.900 --> 00:00:07.839
00:00:08.169 --> 00:00:13.210
00:00:14.529 --> 00:00:28.089
00:00:28.870 --> 00:00:37.570
00:00:38.560 --> 00:00:44.590
00:00:45.520 --> 00:00:55.030
00:00:55.539 --> 00:01:05.769
00:01:06.730 --> 00:01:12.549
00:01:13.239 --> 00:01:20.829
00:01:21.640 --> 00:01:24.549
00:01:25.000 --> 00:01:25.959
00:01:26.019 --> 00:01:42.280
00:01:42.810 --> 00:01:44.409
00:01:46.450 --> 00:01:52.900
00:01:53.260 --> 00:01:58.810
00:01:58.840 --> 00:02:03.530
00:02:03.599 --> 00:02:10.750
00:02:10.810 --> 00:02:21.870
00:02:22.490 --> 00:02:25.650
00:02:26.129 --> 00:02:37.319
00:02:37.479 --> 00:02:46.629
00:02:46.900 --> 00:02:58.689
00:02:59.270 --> 00:03:14.930
00:03:15.020 --> 00:03:26.000
00:03:26.001 --> 00:03:39.650
00:03:40.340 --> 00:03:44.719
00:03:45.199 --> 00:03:53.389
00:03:53.390 --> 00:04:06.770
00:04:06.800 --> 00:04:11.449
00:04:11.569 --> 00:04:15.620
00:04:15.919 --> 00:04:19.129
00:04:19.130 --> 00:04:23.810
00:04:24.259 --> 00:04:27.529
00:04:28.009 --> 00:04:31.670
00:04:32.569 --> 00:04:52.370
00:04:52.970 --> 00:05:02.540
00:05:02.839 --> 00:05:15.110
00:05:15.139 --> 00:05:27.199
00:05:27.560 --> 00:05:29.720
00:05:29.721 --> 00:05:34.279
00:05:34.281 --> 00:05:44.120
00:05:44.120 --> 00:05:56.180
00:05:56.269 --> 00:06:01.399
00:06:01.699 --> 00:06:05.629
00:06:05.630 --> 00:06:23.990
00:06:24.139 --> 00:06:30.410
00:06:30.740 --> 00:06:52.939
00:06:53.420 --> 00:07:04.370
00:07:04.620 --> 00:07:06.889
00:07:07.370 --> 00:07:13.100
00:07:13.730 --> 00:07:20.480
00:07:20.509 --> 00:07:31.339
00:07:31.939 --> 00:07:36.500
00:07:36.980 --> 00:07:37.759
00:07:37.761 --> 00:07:47.509
00:07:47.511 --> 00:07:59.509
00:07:59.810 --> 00:08:11.589
00:08:11.589 --> 00:08:16.480
00:08:16.839 --> 00:08:17.620
00:08:18.069 --> 00:08:20.709
00:08:21.459 --> 00:08:25.810
00:08:26.230 --> 00:08:41.919
00:08:42.129 --> 00:08:44.950
00:08:45.190 --> 00:08:48.279
00:08:48.460 --> 00:09:07.080
00:09:07.350 --> 00:09:13.049
00:09:13.429 --> 00:09:14.389
00:09:14.419 --> 00:09:14.779
00:09:14.960 --> 00:09:27.740
00:09:27.740 --> 00:09:34.490
00:09:34.879 --> 00:09:42.740
00:09:43.370 --> 00:09:45.799
00:09:46.009 --> 00:09:46.490
00:09:46.549 --> 00:09:48.950
00:09:48.951 --> 00:09:50.419
00:09:50.629 --> 00:09:55.700
00:09:55.701 --> 00:09:58.259
00:09:58.820 --> 00:10:02.809
00:10:02.811 --> 00:10:10.039
00:10:10.370 --> 00:10:21.590
00:10:21.591 --> 00:10:36.919
00:10:37.070 --> 00:10:40.159
00:10:40.440 --> 00:10:54.210
00:10:54.389 --> 00:11:00.720
00:11:01.289 --> 00:11:21.629
00:11:21.960 --> 00:11:28.679
00:11:29.129 --> 00:11:31.080
00:11:31.470 --> 00:11:44.399
00:11:44.399 --> 00:11:48.000
00:11:48.360 --> 00:12:07.129
00:12:07.159 --> 00:12:10.759
00:12:11.929 --> 00:12:12.799
00:12:13.909 --> 00:12:22.549
00:12:22.580 --> 00:12:23.960
00:12:23.961 --> 00:12:25.009
00:12:25.039 --> 00:12:34.309
00:12:34.311 --> 00:12:43.250
00:12:43.789 --> 00:12:45.350
00:12:45.429 --> 00:12:47.870
00:12:48.159 --> 00:12:50.830
00:12:51.230 --> 00:12:51.590
00:12:51.649 --> 00:12:52.269
00:12:52.580 --> 00:12:53.179
00:12:53.409 --> 00:12:53.679
00:12:53.840 --> 00:12:59.240
00:12:59.240 --> 00:13:02.629
00:13:03.049 --> 00:13:03.379
00:13:03.380 --> 00:13:04.250
00:13:04.639 --> 00:13:04.750
00:13:04.909 --> 00:13:05.179
00:13:05.629 --> 00:13:06.200
00:13:06.201 --> 00:13:06.440